GlassScriptPhysician profile
Henry C Lin
NPI 1649483033
$211.77
in general payments reported to CMS, 2019-2025
4 companies · $22.78 in 2025
The $22.78 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $50.22 · 2021: $79.69 · 2022: $59.08 · 2025: $22.78.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $22.78.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $22.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $118.64 | 2021-2022 | |
| Pfizer INC. | $50.22 | 2019 | |
| Gilead Sciences, INC. | $22.78 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.13 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Henry Lin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.